Novartis To Petition U.S. Supreme Court To Uphold Patent Validity Of Gilenya Dosing Regimen

Swiss drug major Novartis AG (NVS) announced Wednesday it plans to file a petition to the U.S. Supreme Court to uphold validity of the Gilenya (fingolimod) dosing regimen patent.

The decision comes as the U.S. Court of Appeals for the Federal Circuit or CAFC has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya.

Novartis said it plans to seek further review of the CAFC's decision with the US Supreme Court.

The U.S. District Court for the District of Delaware in August 2020 issued a favorable decision and a permanent injunction was granted against HEC Pharma until the expiration of the '405 patent in December 2027, including pediatric exclusivity.

HEC Pharma was the only remaining Abbreviated New Drug Application or ANDA filer challenging this patent.

In January 2022, CAFC's three-judge panel issued a decision upholding the validity of the dosing regimen patent. HEC subsequently filed a petition for rehearing with the CAFC. In June 2022, a modified panel from the CAFC issued a reversal of its previous decision and found the patent invalid.

Novartis entered into settlement agreements with a number of ANDA filers earlier, under which those ANDA filers would have been able to launch a generic version of Gilenya, if approved by FDA, on an agreed upon date that is prior to the expiration of the dosing regimen patent, or earlier than the agreed upon date under certain circumstances.

With the latest decision, HEC and other ANDA filers with FDA approval will potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions.

Novartis said it intends to vigorously defend the validity of the patent and is considering all available options, including current plans to seek review of this decision by petition to the US Supreme Court. The process is likely to take several months to determine if the petition will be granted.

Regarding the financial impact, Novartis now said, "Should generics launch in the US, we expect FY 2022 sales to be negatively impacted by USD 0.3bn. With regard to 2022 Full Year Guidance for Group sales and core operating income growth, we continue to expect both in the mid-single digit range, in constant currencies."

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT